443 related articles for article (PubMed ID: 23950209)
1. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
[TBL] [Abstract][Full Text] [Related]
2. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene.
Fontanals-Cirera B; Hasson D; Vardabasso C; Di Micco R; Agrawal P; Chowdhury A; Gantz M; de Pablos-Aragoneses A; Morgenstern A; Wu P; Filipescu D; Valle-Garcia D; Darvishian F; Roe JS; Davies MA; Vakoc CR; Hernando E; Bernstein E
Mol Cell; 2017 Nov; 68(4):731-744.e9. PubMed ID: 29149598
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Echevarría-Vargas IM; Reyes-Uribe PI; Guterres AN; Yin X; Kossenkov AV; Liu Q; Zhang G; Krepler C; Cheng C; Wei Z; Somasundaram R; Karakousis G; Xu W; Morrissette JJ; Lu Y; Mills GB; Sullivan RJ; Benchun M; Frederick DT; Boland G; Flaherty KT; Weeraratna AT; Herlyn M; Amaravadi R; Schuchter LM; Burd CE; Aplin AE; Xu X; Villanueva J
EMBO Mol Med; 2018 May; 10(5):. PubMed ID: 29650805
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.
Gallagher SJ; Mijatov B; Gunatilake D; Tiffen JC; Gowrishankar K; Jin L; Pupo GM; Cullinane C; Prinjha RK; Smithers N; McArthur GA; Rizos H; Hersey P
J Invest Dermatol; 2014 Nov; 134(11):2795-2805. PubMed ID: 24906137
[TBL] [Abstract][Full Text] [Related]
6. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
7. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
[TBL] [Abstract][Full Text] [Related]
8. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.
Ozer HG; El-Gamal D; Powell B; Hing ZA; Blachly JS; Harrington B; Mitchell S; Grieselhuber NR; Williams K; Lai TH; Alinari L; Baiocchi RA; Brinton L; Baskin E; Cannon M; Beaver L; Goettl VM; Lucas DM; Woyach JA; Sampath D; Lehman AM; Yu L; Zhang J; Ma Y; Zhang Y; Spevak W; Shi S; Severson P; Shellooe R; Carias H; Tsang G; Dong K; Ewing T; Marimuthu A; Tantoy C; Walters J; Sanftner L; Rezaei H; Nespi M; Matusow B; Habets G; Ibrahim P; Zhang C; Mathé EA; Bollag G; Byrd JC; Lapalombella R
Cancer Discov; 2018 Apr; 8(4):458-477. PubMed ID: 29386193
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA
Pistoni M; Rossi T; Donati B; Torricelli F; Polano M; Ciarrocchi A
Mol Cancer Res; 2021 May; 19(5):799-811. PubMed ID: 33547232
[TBL] [Abstract][Full Text] [Related]
12. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
13. FAM222A, Part of the BET-Regulated Basal Endothelial Transcriptome, Is a Novel Determinant of Endothelial Biology and Angiogenesis-Brief Report.
Tzani A; Haemmig S; Cheng HS; Pérez-Cremades D; Heuschkel MA; Jamaiyar A; Singh SA; Aikawa M; Yu PB; Wang T; Sun Y; Feinberg MW; Plutzky J
Arterioscler Thromb Vasc Biol; 2024 Jan; 44(1):143-155. PubMed ID: 37942611
[TBL] [Abstract][Full Text] [Related]
14. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
15. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
16. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.
Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL
Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600
[TBL] [Abstract][Full Text] [Related]
20. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
